Human Complement-Fixing Antibodies in Transplantation

  • G. Hale
  • H. Waldmann


It is widely expected that monoclonal antibodies will find many applications in transplantation. They certainly offer significant advantages of exquisite (even if not always predictable) specificity and continuous availability compared with polyclonal antisera. Four major categories of use will be considered here.


Paroxysmal Nocturnal Hemoglobinuria Autologous Bone Marrow Transplantation Severe Combine Immunodeficiency Human Complement Leukocyte Common Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Clark, M., Cobbold, S., Hale, G., and Waldmann, H., 1983, Advantages of rat monoclonal antibodies, Immunol. Today 4:100–101.CrossRefGoogle Scholar
  2. 2.
    Ritz, J., Sallan, S. E., Bast, R. C., Lipton, J. M., Clavell, L. A., Feeney, M., Hercend, T., Nathan, D. G., and Schlossman, S. F., 1983, Autologous bone marrow transplantation in cALLa positive acute lymphoblastic leukemia after in vitro treatment with J5 monoclonal antibody and complement, Lancet 2:60–63.Google Scholar
  3. 3.
    Sharp, T. G., Sachs, D. H., Fauci, A. S., Messerschmidt, G. L., and Rosenberg, S. A., 1983, T cell depletion of human bone marrow using monoclonal antibody and complement mediated lysis, Transplantation 35:112–120.PubMedCrossRefGoogle Scholar
  4. 4.
    Prentice, H. G., Blacklock, H. A., Janossy, G., Gilmore, M. J. M. L., Price-Jones, L., Tidman, N., Trejdosiewicz, L. K., and Skeggs, D. B. L., Panjwani, D., Ball, S., Graphakos, S., Patterson, J., and Hoffbrand, A. V., 1984, Depletion of T lymphocytes in donor marrow prevents significant graft versus host disease in matched allogeneic leukemic marrow transplant recipients, Lancet 1:472–476.PubMedCrossRefGoogle Scholar
  5. 5.
    Jansen, J., Falkenburg, J. H. F., Stepan, D. E., and LeBien, T. W., 1984, Removal of neoplastic cells from autologous bone marrow grafts with monoclonal antibodies, Sem. Haematol. 21:164–181.Google Scholar
  6. 6.
    Stepan, D. E., Bartholomew, R. M., and LeBien, T. W., 1984, in vitro cytodestruction of human leukemic cells using murine monoclonal antibodies and human complement, Blood 63:1120–1125.PubMedGoogle Scholar
  7. 7.
    Borsos, T., and Rapp, H. J., 1965, Complement fixation on cell surfaces by 19S and 7S antibodies, Science 150:505–506.PubMedCrossRefGoogle Scholar
  8. 8.
    Hughes-Jones, N. C., and Ghosh, S., 1981, Anti-D-coated Rh positive red cells will bind the first component of the complement pathway, C1q, FEBS Lett. 128:318–320.PubMedCrossRefGoogle Scholar
  9. 9.
    Klaus, G. G. B., Pepys, M. B., Kitajima, K., and Askonas, B. A., 1979, Activation of mouse complement by different classes of mouse antibody, Immunology 38:687–695.PubMedGoogle Scholar
  10. 10.
    Neuberger, M. S., and Rajewsky, K., 1981, Activation of mouse complement by monoclonal mouse antibodies, Eur. J. Immunol. 11:1012–1016.PubMedCrossRefGoogle Scholar
  11. 11.
    Oi, V. T., Vuong, T. M., Hardy, R., Reidler, J., Dangl, J., Herzenberg, L. A., and Stryer, L., 1984, Correlation between segmental flexibility and effector function of antibodies, Nature 307:136–140.PubMedCrossRefGoogle Scholar
  12. 12.
    Fust, G., Medgyesi, G. A., Bazin, H., and Gergely, J., 1980, Differences in the ability of rat IgG subclasses to consume complement in homologous and heterologous serum, Immunol. Lett. 1:249–253.CrossRefGoogle Scholar
  13. 13.
    Hughes-Jones, N. C., Gorick, B. D., and Howard, J. C., 1983, The mechanism of synergistic complement-mediated lysis of rat red cells by monoclonal IgG antibodies, Eur. J. Immunol. 13:635–640.PubMedCrossRefGoogle Scholar
  14. 14.
    Borsos, T., Rapp, H. J., and Mayer, M. M., 1961, Studies on the second component of complement. I. The reaction between EAC’1,4 and C’2: Evidence on the single site mechanism of immune hemolysis and determination of C’2 on a molecular basis, J. Immunol. 87:310–325.Google Scholar
  15. 15.
    Koski, C. L., Ramm, L. E., Hammer, C. H., Mayer, M. M., and Shin, M. L., 1983, Cytolysis of nucleated cells by complement: Cell death displays multi hit characteristics, Proc. Natl. Acad. Sci. USA 80:3816–3820.PubMedCrossRefGoogle Scholar
  16. 16.
    Lerner, R. A., Oldstone, M. B., and Cooper, N. R., 1971, Cell-cycle dependent immune lysis of Moloney virus transformed lymphocytes: Presence of viral antigens, accessibility to antibody and complement activation, Proc. Nat. Acad. Sci. USA 68:2584–2588.PubMedCrossRefGoogle Scholar
  17. 17.
    Ohanian, S. H., Borsos, T., and Rapp, H. J., 1973, Lysis of tumour cells by antibody and complement 1. Lack of correlation between antigen content and lytic susceptibility, J. Natl. Cancer Inst. 50:1313–1320.PubMedGoogle Scholar
  18. 18.
    Boyse, E. A., and Old, L. J., 1969, Some aspects of normal and abnormal cell surface genetics, Annu. Rev. Genet. 3:269–291.CrossRefGoogle Scholar
  19. 19.
    Gordon, J., Daniele, S., Robinson, F., and Stevenson, G. T., 1981, Antigenic modulation of lymphocyte surface immunoglobulin yielding resistance to complement-mediated lysis I. Characterization with syngeneic and xenogeneic complements, Immunology 42:7–12.PubMedGoogle Scholar
  20. 20.
    Stackpole, C. W., Jacobson, J. B., and Lardis, M. P., 1974, Antigenic modulation in vivo I. Fate of thymus leukemia (TL) antigen-antibody complexes following modulation of TL antigenicity from the surfaces of mouse leukemia cells and thymocytes, J. Exp. Med. 140:939–953.PubMedCrossRefGoogle Scholar
  21. 21.
    Taylor, R. B., Duffus, W. P. H., Raff, M. C., and de Pétris, S., 1971, Redistribution and pinocytosis of lymphocyte surface immunoglobulin molecules induced by anti-immunoglobulin antibody, Nature 233:225–229.CrossRefGoogle Scholar
  22. 22.
    Schreiner, G. F. and Unanue, E. R., 1976, Membrane and cytoplasmic changes in B lymphocytes induced by ligand-surface immunoglobulin interaction, Adv. Immunol. 24:37–165.PubMedCrossRefGoogle Scholar
  23. 23.
    Gordon, J., and Stevenson, G. T., 1981, Antigenic modulation of lymphocyte surface immunoglobulin yielding resistance to complement-mediated lysis. II. Relationship to redistribution of the antigen, Immunology 42:13–17.PubMedGoogle Scholar
  24. 24.
    Gordon, J., Anderson, V. A., and Stevenson, G. T., 1982, Loss of surface-bound antibody accompanying the anti-complementary modulation of leukemic B cell immunoglobulin: Contrasting effects of antibodies directed against idiotypic and constant regions, J. Immunol. 128:2763–2769.Google Scholar
  25. 25.
    Hansch, G. M., Hammer, C. H., Vanguri, P., and Shin, M. L., 1981, Homologous species restriction in lysis of erythrocytes by terminal complement proteins, Proc. Natl. Acad. Sci. USA 78:5118–5121.PubMedCrossRefGoogle Scholar
  26. 26.
    Pangburn, M. K., Schreiber, R. D., and Muller-Eberhard, H. J., 1983, Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria, Proc. Natl. Acad. Sci. USA 80:5430–5434.PubMedCrossRefGoogle Scholar
  27. 27.
    Okada, H., Tanaka, H., and Okada, N., 1983, Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes, Eur. J. Immunol. 13:340–344.PubMedCrossRefGoogle Scholar
  28. 28.
    Kasubowski, P. A., Terasaki, P. I., Chia, D. S., Kukes, G. D., Hardiwidjaja, S. I., and Cicciarelli, J. C., 1984, A cytotoxic monoclonal antibody to colon adenocarcinoma, Cancer Res. 44:1194–1199.Google Scholar
  29. 29.
    Springer, T. A., Bhattacharya, A., Cardoza, J. T., and Sanchez-Madrid, F., 1982, Monoclonal antibodies specific for rat IgG1, IgG2a and IgG2b subclasses and kappa chain monotypic and allotypic determinants: Reagents for use with rat monoclonal antibodies, Hybridoma 1:257–273.PubMedCrossRefGoogle Scholar
  30. 30.
    Aqel, N. M., Clark, M., Cobbold, S. P., and Waldmann, H., 1984, Immunohistological screening in the selection of monoclonal antibodies: The use of isotype-specific antiglobulins, J. Immunol. Meth. 69:207–214.CrossRefGoogle Scholar
  31. 31.
    Bazin, H., Beckers, A., and Querinjean, P., 1974, Three classes and four subclasses of rat immunoglobulins: IgM, IgA, IgE, and IgGl, IgG2a, IgG2b, IgG2c, Eur. J. Immunol. 4:44–48.PubMedCrossRefGoogle Scholar
  32. 32.
    Springer, T. A., 1980, Cell surface differentiation in the mouse: Characterization of jumping and lineage specific antigens using xenogeneic rat monoclonal antibodies, in: Monoclonal Antibodies (R. Kennett, T. McKearn, and K. Bechtol, eds.), Plenum Press, New York, pp. 185–217.CrossRefGoogle Scholar
  33. 33.
    Milstein, C. and Cuello, C., 1983, Hybrid myelomas and their use in immunohistochemistry, Nature 305:537–540.PubMedCrossRefGoogle Scholar
  34. 34.
    Rodt, H., Kolb, H. J., Netzel, B., Rieder, I., Janka, G., Belohradsky, B., Haas, R. J., and Thierfelder, S., 1979, GVHD suppression by incubation of bone marrow grafts with anti-T cell globulin: Effect in the canine model and application to clinical bone marrow transplantation, Transplant. Proc. 11:962–966.PubMedGoogle Scholar
  35. 35.
    Vallera, D. A., Soderling, C. C. R., Carlson, G. J., and Kersey, J. H., 1981, Bone marrow transplantation across major histocompatibility barriers in mice. Effect of elimination of T cells from donor grafts by pretreatment with monoclonal anti-Thy-1 plus complement or antibody alone, Transplantation 31:218–222.PubMedCrossRefGoogle Scholar
  36. 36.
    Wagemaker, G., Vriesendorp, H. M., and van Bekkum, D. W., 1981, Successful bone marrow transplantation across major histocompatibility barriers in rhesus monkeys, Transplant. Proc. 13:875–830.PubMedGoogle Scholar
  37. 37.
    Reisner, Y., Kapoor, N., Kirkpatrick, D., Pollack, M. S., Cunningham-Rundles, S., Dupont, B., Hodes, M. Z., and Good, R. A., O’Reilly, R. J., 1983, Transplantation for severe combined immunodeficiency with HLA-A,B,C,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells, Blood 61:341–348.PubMedGoogle Scholar
  38. 38.
    Filipovich, A. H., Vallera, D. A., Youle, R. J., Quinones, R. A., Neville, D. M., and Kersey, J. H., 1984, Ex vivo treatment of donor bone marrow with anti-T cell immunotoxins for the prevention of graft versus host disease, Lancet 1:469–472.PubMedCrossRefGoogle Scholar
  39. 39.
    Gilmore, M. J. M. L., Prentice, H. G., Price Jones, E., Blacklock, H. A., Tidman, N., Schey, S., Goldstein, G., Janossy, G., and Hoffbrand, A. V., 1983, Allogeneic bone marrow transplantation: The monitoring of granulocyte macrophage colonies following the collection of bone marrow mononuclear cells and after the subsequent in vitro cytolysis of OKT3 positive lymphocytes, Br. J. Haematol. 55:587–593.PubMedCrossRefGoogle Scholar
  40. 40.
    Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D., Munro, A. J., and Waldmann, H., 1983, Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement, Blood 62:873–882.PubMedGoogle Scholar
  41. 41.
    Hale, G., Hoang, T., Prospero, T., Watt, S. M., and Waldmann, H., 1983, Removal of T cells from bone marrow for transplantation: Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes, Mol. Biol. Med. 1:305–319.PubMedGoogle Scholar
  42. 42.
    Waldmann, H., Or, R., Hale, G., Weiss, L., Cividalli, G., Samuel, S., Manor, D., Brautbar, C., Polliack, A., Rachmilewitz, E. A., and Slavin, S., 1984, Elimination of graft versus host disease by in vitro depletion of alloreactive lymphocytes using a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1), Lancet 2:483–486.PubMedCrossRefGoogle Scholar
  43. 43.
    Witherspoon, R. P., Lum, L. G., and Storb, R., 1984, Immunologic reconstitution after human marrow grafting, Sem. Haematol. 21:2–10.Google Scholar
  44. 44.
    Morgan, G., Linch, D. C., Davies, E. G., Sieff, C., Chessells, J. M. C., Hale, G., Waldmann, H., and Levinsky, R. J., 1985, Successful haploidentical mismatched bone marrow transplantation in severe combined immunodeficiency: T Cell removal using CAMPATH-1 monoclonal antibody plus E rosetting, Br. J. Haematol., In press.Google Scholar
  45. 45.
    Van Bekkum, D. W., 1984, Conditioning regimes for marrow grafting, Sem. Haematol. 21:81–90.Google Scholar
  46. 46.
    Lafferty, K. J., Prowse, S. J., Simeonovic, C. J., and Warren, H. S., 1983, Immunobiology of tissue transplantation: A return to the passenger leucocyte concept, Annu. Rev. Immunol. 1:143–174.PubMedCrossRefGoogle Scholar
  47. 47.
    Silvers, W. K., Bartlett, S. T., Chen, H.-D., Fleming, H. L., Naji, A., and Barker, C. F., 1984, Major histocompatibility complex restriction and transplantation immunity. A possible solution to the allograft problem, Transplantation 37:28–32.PubMedCrossRefGoogle Scholar
  48. 48.
    Dicke, K. A., Jagannath, S., Spitzer, G., Poynton, C., Zander, A., Vellekoop, L., Reading, C. L., Jehn, U. W., and Tindle, S., 1984, The role of autologous bone marrow transplantation in various malignancies, Sem. Haematol. 21:109–122.Google Scholar
  49. 49.
    Treleavan, J. G., Gibson, F. M., Ugelstad, J., Rembaum, A., Philip, T., Caine, G. D., and Kemshead, J. T., 1984, Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres, Lancet 1:70–73.CrossRefGoogle Scholar
  50. 50.
    Hale, G., Swirsky, D., Waldmann, H., and Chan, L. C., 1984, Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation, Br. J. Haematol. 60:41–48.CrossRefGoogle Scholar
  51. 51.
    Hale, G., Swirsky, D. M., Hayhoe, F. G. J., and Waldmann, H., 1983, Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans, Mol. Biol. Med. 1:321–334.PubMedGoogle Scholar
  52. 52.
    Zwaan, F. E., and Jansen, J., 1984, Bone marrow transplantation in acute nonlymphoblastic leukemia, Sem. Haematol. 21:36–42.Google Scholar
  53. 53.
    Buckner, C. D., and Clift, R. A., 1984, Marrow transplantation for acute lymphoblastic leukemia, Sem. Haematol. 21:43–47.Google Scholar
  54. 54.
    Speck, B., Gratwohl, A., Osterwalder, B., and Nissen, C., 1984, Bone marrow transplantation for chronic myeloid leukemia, Sem. Haematol. 21:48–52.Google Scholar
  55. 55.
    Ritz, J., and Schlossman, S. F., 1982, Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma, Blood 59:1–11.PubMedGoogle Scholar
  56. 56.
    Cosimi, A. B., 1981, The clinical value of anti-lymphocyte globulin, Transplant. Proc. 13:462–468.PubMedGoogle Scholar
  57. 57.
    Harkiss, G. D., Brown, D. L., Cory-Pearce, R., and English, T. A. H., 1983, Serial analysis of circulating immune complexes, complement and anti-thymocyte globulin antibodies in heart transplant patients, J. Clin. Immunol. 3:117–126.PubMedCrossRefGoogle Scholar
  58. 58.
    Calne, R. Y., 1980, Transplant surgery: Current status, Br. J. Surg. 67:765–771.PubMedCrossRefGoogle Scholar
  59. 59.
    Calne, R. Y., 1984, Paratopic segmental pancreas grafting: A technique with portal venous drainage, Lancet 1:595–597.PubMedCrossRefGoogle Scholar
  60. 60.
    Oldham, R. K., 1983, Monoclonal antibodies in cancer therapy, J. Clin. Oncol. 1:582–590.PubMedGoogle Scholar
  61. 61.
    Levy, R., and Miller, R. A., 1983, Biological and clinical implications of lymphocyte hybridomas: Tumor therapy with monoclonal antibodies, Annu. Rev. Med. 34:107–116.PubMedCrossRefGoogle Scholar
  62. 62.
    Shield, C. F., Cosimi, A. B., Tolkoff-Rubin, N., Rubin, R. N., Herrin, J., and Russell, P. S., 1979, Use of antithymocyte globulin for reversal of acute allograft rejection, Transplantation 28:461–464.PubMedGoogle Scholar
  63. 63.
    Cosimi, A. B., Burton, R. C., Colvin, R. B., Goldstein, C., Delmonico, F. L., LaQuaglia, M. P., Tolkoff-Rubin, N., Rubin, R. H., Herrin, J. T., and Russell, P. S., 1981, Treatment of acute renal allograft rejection with OKT3 monoclonal antibody, Transplantation 32:535–539.PubMedCrossRefGoogle Scholar
  64. 64.
    Nelson, P. W., Cosimi, A. B., Delmonico, F. L., Rubin, R. H., Tolkoff-Rubin, N. E., Fang, L., and Russell, P. S., 1983, Antithymocyte globulin as the primary treament for renal allograft rejection, Transplantation 36:587–589.PubMedCrossRefGoogle Scholar
  65. 65.
    Takahashi, H., Okazaki, H., Terasaki, P. I., Iwaki, Y., Kinukawa, T., Taguchi, Y., Chia, D., Hardiwidjaja, S., Miura, K., Ishizaki, M., and Billing, R., 1983, Reversal of transplant rejection by monoclonal antiblast antibody, Lancet 2:1155–1157.PubMedCrossRefGoogle Scholar
  66. 66.
    Dresser, D. W. and Wortis, H. H., 1965, Use of an antiglobulin serum to detect cells producing antibody with low haemolytic efficiency, Nature 208:859–860.PubMedCrossRefGoogle Scholar
  67. 67.
    Fitchen, J. H., Ruisso, C., and Ferrone, S., 1984, Complement-dependent killing of human hematopoietic progenitor cells with non complement-fixing monoclonal antibodies in an antiglobulin assay, Blood 63:873–877.PubMedGoogle Scholar
  68. 68.
    Tanimoto, K., Cooper, N. R., Johnson, J. S., and Vaughan, J. H., 1975, Complement fixation by rheumatoid factor, J. Clin. Invest. 55:437–445.PubMedCrossRefGoogle Scholar
  69. 69.
    Carson, D. A., 1984, Increase in the complement-fixing ability of murine IgG anti-lymphocyte antibodies by addition of monoclonal IgM rheumatoid factors, J. Immunol. Meth. 68:103–108.CrossRefGoogle Scholar
  70. 70.
    Lanier, L. L., Gutman, G. A., Lewis, D. E., Griswold, S. T., and Warner, N. L., 1982, Monoclonal antibodies against rat immunoglobulin kappa chains, Hybridoma 1:125–131.PubMedCrossRefGoogle Scholar
  71. 71.
    Langone, J. J., 1982, Enhancing effect of concanavalin A on the hemolytic effect of anti-Forssman IgG: The role of C1, J. Immunol. 129:1159–1164.PubMedGoogle Scholar
  72. 72.
    Langone, J. J., Boyle, M. D. P., and Borsos, T., 1984, Studies on the interaction between protein A and immunoglobulin G. 1. Effect of protein A on the functional activity of IgG, J. Immunol. 131:327–332.Google Scholar
  73. 73.
    Elliot, E. V., Pinder, A., Stevenson, F. K., and Stevenson, G. T., 1978, Synergistic cytotoxic effects of antibodies directed against different cell surface determinants, Immunology 34:405–409.Google Scholar
  74. 74.
    Howard, J. C., Butcher, J. W., Galfre, G., Milstein, C., and Milstein, C. P., 1979, Monoclonal antibodies as tools to analyse the serological and genetic complexities of major transplantation antigens, Immunol. Rev. 47:139–175.PubMedCrossRefGoogle Scholar
  75. 75.
    Bindon, C. I., Hale, G., Clark, M., and Waldmann, H., 1985, Therapeutic potential of monoclonal antibodies to the leucocyte common antigen: Synergy and interference in complement-mediated lysis, J. Immunol., In press.Google Scholar
  76. 76.
    Dalchau, R., Kirkley, J., and Fabre, J. W., 1980, Monoclonal antibody to a human leukocyte specific membrane glycoprotein probably homologous to the leukocyte common antigen of the rat, Eur. J. Immunol. 10:737–744.PubMedCrossRefGoogle Scholar
  77. 77.
    Glennie, M. J., and Stevenson, G. T., 1982, Univalent antibodies kill tumour cells in vitro and in vivo, Nature 295:712–714.PubMedCrossRefGoogle Scholar
  78. 78.
    Cobbold, S. P., and Waldmann, H., 1984, Therapeutic potential of monovalent monoclonal antibodies, Nature 308:460–462.PubMedCrossRefGoogle Scholar
  79. 79.
    Cotton, R. G. H., and Milstein, C., 1973, Fusion of two immunoglobulin-producing myeloma cells, Nature 244:42–43.PubMedCrossRefGoogle Scholar
  80. 80.
    Galfre, G., Milstein, C., and Wright, B., 1979, Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG, Nature 277:131–133.PubMedCrossRefGoogle Scholar
  81. 81.
    Schlager, S. I., Ohanian, S. H., and Borsos, T., 1978, Correlation between the ability of tumor cells to resist humoral immune attack and their ability to synthesize lipid, J. Immunol. 120:463–471.PubMedGoogle Scholar
  82. 82.
    Schlager, S. I., 1982, Relationship between cell-mediated and humoural immune attack on tumour cells II. The role of cellular lipid metabolism and cell surface charge in the outcome of immune attack, Cell. Immunol. 66:300–316.PubMedCrossRefGoogle Scholar
  83. 83.
    Segerling, M., Ohanian, S. H., and Borsos, T., 1975, Chemotherapeutic drugs increase killing of tumor cells by antibody and complement, Science 188:55–56.PubMedCrossRefGoogle Scholar
  84. 84.
    Hansch, G. M., Betz, M., and Shin, M., 1984, Cytolysis of nucleated cells by complement. Inhibition of membrane transmethylation enhances cell death by C5b-9, J. Immunol. 132:1440–1444.PubMedGoogle Scholar
  85. 85.
    Waldmann, H., Cobbold, S., Wilson, A., Clark, M., Watt, S., Hale, C., and Tighe, H., 1985, Rat monoclonal antibodies for bone marrow transplantation—The CAMPATH series, in: Microenvironments in the Lymphoid System, (G. G. B. Klaus, ed.), Plenum Press, New York, pp. 869–878.CrossRefGoogle Scholar
  86. 86.
    Hunt, S. V., and Fowler, M. H., 1981, A repopulation assay for B and T lymphocyte stem cells employing radiation chimaeras, Cell Tiss. Kinet. 14:445–464.Google Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • G. Hale
    • 1
  • H. Waldmann
    • 1
  1. 1.Department of Pathology, Division of Immunology, New Addenbrookes HospitalUniversity of CambridgeCambridgeEngland

Personalised recommendations